Anixa Biosciences Inc
ANIX
NASDAQ
Biotechnology
$3.18
USD
-0.02 (-0.63%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $109.89M
Volume 107.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-10.12M
TTM
+17.4%
YoY
Operating Cash Flow
$-7.12M
TTM
+10.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.7 | 1.4 | 1.7 | 1.6 | 1.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.0 | 2.4 | 2.9 | 2.7 | 2.6 |
Operating Income | -3.0 | -2.4 | -2.9 | -2.7 | -2.6 |
EBITDA | -3.0 | -2.4 | -2.9 | -2.7 | -2.6 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
Income Before Income Taxes | -2.8 | -2.3 | -2.7 | -2.6 | -2.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.8 | -2.3 | -2.7 | -2.6 | -2.5 |
Consolidated Net Income / Loss | -2.8 | -2.3 | -2.7 | -2.6 | -2.5 |
Net Income Attributable to Common Shareholders | -2.8 | -2.3 | -2.7 | -2.6 | -2.5 |
Basic EPS | -$0.09 | -$0.07 | -$0.08 | -$0.08 | -$0.07 |
Diluted EPS | -$0.09 | -$0.07 | -$0.08 | -$0.08 | -$0.07 |
Basic Shares Outstanding | 32.2M | 32.5M | 32.9M | 33.2M | 33.6M |
Diluted Shares Outstanding | 32.2M | 32.5M | 32.9M | 33.2M | 33.6M |